Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | CREBBP | Q92793 | 11/20 | 0.53 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20601847 | 0.84 | L3MBTL1 (0.44) | L3MBTL1CREBBPKDM4ECYP2C9SMN1; SMN2 | |
| SCHEMBL20602517 | 0.78 | NAMPT (0.43) | L3MBTL1CREBBPPDK2MAPK1KDM4E | |
| SCHEMBL31058725 | 0.78 | NAMPT (0.43) | L3MBTL1CREBBPPDK2MAPK1KDM4E | |
| SCHEMBL10094644 | 0.78 | CREBBP (0.69) | L3MBTL1CREBBPPDK2PIK3CDADORA2A | |
| SCHEMBL10094636 | 0.76 | L3MBTL1 (0.59) | L3MBTL1CREBBPPIK3CDADORA2AADORA1 | |
| SCHEMBL19049794 | 0.76 | LRRK2 (0.45) | CREBBPPDK2KDM4EPIK3CD | |
| SCHEMBL509619 | 0.76 | BTK (0.49) | L3MBTL1CREBBPPDK2SMN1; SMN2ADORA2A | |
| SCHEMBL510899 | 0.75 | BTK (0.58) | L3MBTL1CREBBPPDK2ADORA2AADORA1 | |
| SCHEMBL10094327 | 0.74 | L3MBTL1 (0.60) | L3MBTL1CREBBPPDK2PIK3CDADORA2A | |
| SCHEMBL3289673 | 0.74 | L3MBTL1 (0.56) | L3MBTL1CREBBPMAPK1ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822514-B2 | Multi-cyclic compounds and methods of use | AMGEN INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20120245206-A1 | MULTI-CYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-8236823-B2 | Multi-cyclic compounds and methods of use | AMGEN INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20080255205-A1 | protein kinase receptors (like Tie-2 and Aurora) modulators; to treat cancer, inflammation and related disorders; to regulate active angiogenesis, cell-signal transduction; 5-(3-(1H-tetrazol-5-yl)pyridin-2-yloxy)-N-(3-chlorobenzyl)-2-fluorobenzamide | AMGEN INC. (US) | 2008-10-16 | — | — | US | disclosed |
| WO-2008057280-A1 | MULTI-CYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245206-A1 | MULTI-CYCLIC COMPOUNDS AND METHODS OF USE | TIE1, FLT4, CDK1 | L3MBTL1 3021/4885CREBBP 1593/4885PDK2 491/4885 |
| US-20080255205-A1 | protein kinase receptors (like Tie-2 and Aurora) modulators; to treat cancer, inflammation and related disorders; to regulate active angiogenesis, cell-signal transduction; 5-(3-(1H-tetrazol-5-yl)pyridin-2-yloxy)-N-(3-chlorobenzyl)-2-fluorobenzamide | TIE1, AURKB, TEK | L3MBTL1 2047/4885CREBBP 1229/4885PDK2 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.